Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Newport Pharmaceuticals International |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002059 |
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to:
Condition | Intervention |
---|---|
HIV Infections |
Drug: Inosine pranobex |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind |
Official Title: | A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded:
Concurrent Treatment:
Excluded:
The following are excluded:
Prior Medication:
Excluded:
Patients who fall into the group which is at risk of developing cutaneous sarcoma and/or opportunistic diseases but at present have no signs or symptoms of these diseases.
Study ID Numbers: | 008E, ISO-133-USA |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002059 |
Health Authority: | United States: Food and Drug Administration |
T-Lymphocytes, Suppressor-Effector Neoplasms Inosine Pranobex Killer Cells |
T-Lymphocytes, Helper-Inducer Acquired Immunodeficiency Syndrome AIDS-Related Complex |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome |
AIDS-Related Complex Inosine Pranobex Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections Slow Virus Diseases Immunologic Factors Immune System Diseases Therapeutic Uses |
Physiological Effects of Drugs Adjuvants, Immunologic Lentivirus Infections Infection Antiviral Agents Pharmacologic Actions |